Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $164 | $703 | $1,378 | $1,378 |
| - Cash | $48 | $170 | $111 | $27 |
| + Debt | $38 | $27 | $26 | $15 |
| Enterprise Value | $153 | $560 | $1,293 | $1,366 |
| Revenue | $13 | $4 | $9 | $33 |
| % Growth | 201.7% | -55.2% | -71.2% | – |
| Gross Profit | $5 | -$1 | $8 | $32 |
| % Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| EBITDA | -$169 | -$152 | -$75 | -$52 |
| % Margin | -1,334.5% | -3,622.3% | -801.5% | -158.8% |
| Net Income | -$24 | -$20 | -$101 | $12 |
| % Margin | -187% | -482.3% | -1,071.9% | 38.1% |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| % Growth | 5.6% | 75.3% | -912% | – |
| Operating Cash Flow | -$114 | -$109 | -$68 | -$37 |
| Capital Expenditures | -$3 | -$5 | -$4 | -$0 |
| Free Cash Flow | -$117 | -$114 | -$72 | -$37 |